Financial Performance - Puma Biotechnology reported first-quarter 2025 adjusted earnings of 10 cents per share, exceeding the Zacks Consensus Estimate of 2 cents, compared to a loss of 5 cents per share in the same quarter last year [1] - Total revenues for the quarter were $46.0 million, surpassing the Zacks Consensus Estimate of $44.0 million, with a year-over-year increase of 5% attributed to higher product revenues [1][2] - Product revenues from Nerlynx totaled $43.1 million, reflecting a 7% year-over-year increase and slightly above the guidance of $41-$43 million, although there was a sequential decline of 20.7% [5] - Royalty revenues amounted to $2.9 million, down from $3.5 million in the year-ago quarter but exceeding the model estimate of $1.7 million [6] Cost Management - Total operating costs for the quarter were $42.0 million, a decrease of 9% year over year [6] - Selling, general and administrative expenses declined by 19.2% year over year to $17.6 million, primarily due to lower legal fees [6] - Research and development expenses totaled $13.8 million, reflecting a 1.5% year-over-year increase [7] Future Guidance - Puma Biotechnology maintained its financial guidance for 2025, expecting Nerlynx's product sales to be in the range of $192-$198 million and royalty revenues between $20-$24 million [10] - For the second quarter of 2025, Nerlynx product sales are anticipated to be between $48-$50 million, with royalty revenues expected to be in the range of $2-$3 million [11] Pipeline Developments - The company is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer, having in-licensed the rights from Takeda in 2022 [12] - Puma Biotechnology is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy in extensive-stage small-cell lung cancer, with interim data expected in the second half of 2025 [13] - A phase II study (ALISCA-Breast1) is also underway for alisertib in combination with endocrine treatment for chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data expected in the second half of 2025 [14] Stock Performance - Shares of Puma Biotechnology increased by 4.2% in after-hours trading on May 8 due to better-than-expected results [2] - The stock has risen 0.7% year to date, contrasting with an 8.4% decline in the industry [3]